- Home
- STRW vs CTNM Comparison
STRW vs CTNM Comparison
Compare STRW & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRW
- CTNM
- Stock Information
- Founded
- STRW 2015
- CTNM 2009
- Country
- STRW United States
- CTNM United States
- Employees
- STRW N/A
- CTNM N/A
- Industry
- STRW Real Estate Investment Trusts
- CTNM
- Sector
- STRW Real Estate
- CTNM
- Exchange
- STRW Nasdaq
- CTNM Nasdaq
- Market Cap
- STRW 133.6M
- CTNM 154.2M
- IPO Year
- STRW N/A
- CTNM 2024
- Fundamental
- Price
- STRW $10.10
- CTNM $5.80
- Analyst Decision
- STRW Strong Buy
- CTNM Strong Buy
- Analyst Count
- STRW 4
- CTNM 4
- Target Price
- STRW $12.72
- CTNM $22.50
- AVG Volume (30 Days)
- STRW 25.2K
- CTNM 311.7K
- Earning Date
- STRW 08-08-2025
- CTNM 08-12-2025
- Dividend Yield
- STRW 5.53%
- CTNM N/A
- EPS Growth
- STRW 34.22
- CTNM N/A
- EPS
- STRW 0.58
- CTNM N/A
- Revenue
- STRW $126,557,000.00
- CTNM N/A
- Revenue This Year
- STRW $32.86
- CTNM N/A
- Revenue Next Year
- STRW $3.50
- CTNM N/A
- P/E Ratio
- STRW $17.55
- CTNM N/A
- Revenue Growth
- STRW 22.41
- CTNM N/A
- 52 Week Low
- STRW $8.70
- CTNM $3.35
- 52 Week High
- STRW $12.90
- CTNM $20.55
- Technical
- Relative Strength Index (RSI)
- STRW 41.95
- CTNM N/A
- Support Level
- STRW $10.09
- CTNM N/A
- Resistance Level
- STRW $10.80
- CTNM N/A
- Average True Range (ATR)
- STRW 0.30
- CTNM 0.00
- MACD
- STRW -0.01
- CTNM 0.00
- Stochastic Oscillator
- STRW 9.31
- CTNM 0.00
About STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.